Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,234 across all filing types
Latest filing 2026-05-25 Board/Management Inform…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
General Updates
Board/Management Information Classification · 88% confidence The document is an intimation to stock exchanges about the completion of term and cessation of an Independent Director, including details under SEBI Listing Regulations. This is a board management change announcement, not a full report or financial data. Therefore, it classifies as Board/Management Information.
2026-05-25 English
Public Announcement-Open Offer
Regulatory Filings
2026-05-25 English
SBI Capital Markets Limited ("Manager to the Offer") has submitted to BSE a copy of Public Announcement for the attention of the Public Shareholders of Bliss GVS Pharma Ltd under Regulation ....
M&A Activity Classification · 90% confidence The document is a formal public announcement under India’s SEBI (SAST) Regulations outlining an open offer takeover bid by Anupam Rasayan India Limited to acquire up to 26% of Bliss GVS Pharma Limited’s equity shares. It details offer size, price, terms, regulatory triggers, and the underlying share purchase agreement. This is neither a simple report publication notice nor an interim/annual report but rather an M&A takeover announcement. Therefore, it falls under M&A Activity (Code: TAR).
2026-05-25 English
Agreements
M&A Activity Classification · 86% confidence The document is a formal stock exchange disclosure under SEBI Listing Regulations (Reg.30 and 30A) announcing the execution of a Share Purchase Agreement whereby a purchaser will acquire 43.30% equity and trigger a mandatory open offer under SEBI Takeover Regulations. It details counterparties, share counts, special rights, consideration, and open offer obligations, all characteristic of an M&A transaction announcement. Therefore it fits the “M&A Activity” category (Code: TAR).
2026-05-23 English
Please find herewith the disclosures under Regulations 30 and Regulations 30A of the SEBI LODR - Public Announcement for Execution of Share Purchase Agreement.
M&A Activity Classification · 87% confidence The document is a stock exchange disclosure under SEBI Listing Regulations 30/30A announcing the execution of a Share Purchase Agreement (SPA) resulting in an acquisition of a significant block of shares and triggering an open offer under SEBI’s takeover rules. It is not an annual or interim report, audit report, earnings release, or certificate, but rather an M&A-related public announcement of a share purchase and change of control. This falls squarely under M&A Activity (Code: TAR).
2026-05-23 English
Outcome of Board Meeting
M&A Activity Classification · 84% confidence The document is a formal public announcement to stock exchanges under SEBI Listing Regulations (Regulation 30 & 30A) regarding the execution of a Share Purchase Agreement that effects a change in control (43.3% share transfer) and triggers a mandatory open offer under the SEBI (Substantial Acquisition and Takeovers) Regulations. This is clearly related to a takeover/acquisition event rather than a routine financial report, earnings release, or share buyback. Under our taxonomy, announcements concerning takeover bids or share acquisition agreements fall under M&A Activity (Code: TAR).
2026-05-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.